Transgelin is a poor prognostic factor associated with advanced colorectal cancer (CRC) stage promoting tumor growth and migration in a TGFbeta-dependent manner.
Results indicate that TAGLN is a p53 and PTEN-upregulated gene expressing higher levels in normal bladder epithelial cells than in carcinoma cells. Further TAGLN inhibited cell proliferation and invasion in vitro and blocked tumorigenesis in vivo. Collectively it can be concluded that TAGLN is an antitumor gene in the human bladder.
SM22alpha reduction in abdominal aortic aneurysms (AAAs) because of the SM22alpha promoter hypermethylation accelerates AAA formation through the reactive oxygen species/NF-kappaB pathway.
transgelin-1 interacts with actin stress fibers and podosomes in smooth muscle cells via its type-3 CH-domain while CLIK23 is dispensable for the binding to the actin structures
Data (including data from studies using cells cultured from transgenic/knockout mice) suggest that expression and degradation of transgelin in myofibroblasts and keratinocytes are regulated by mechanical tension in cytoskeleton produced by myosin II motor in response to stiffness of culture matrix/extracellular matrix.
SM22 is released into the circulation upon severe ischemia of the intestinal muscle layers. Patients with transmural intestinal ischemia had significantly higher plasma SM22 levels than patients with only ischemic mucosal injury other acute abdominal diseases or healthy controls.
During transition from the pluripotent stage towards the neural developmental stage TAGLN is differentially expressed in bipolar patient derived cells compared to control derived cells.
transgelin (TAGLN) a transforming growth factor beta (TGFbeta)-inducible gene was identified as an upregulated gene during in vitro osteoblastic and adipocytic differentiation of human bone marrow-derived stromal (skeletal) stem cells
this study identified potential biochemical players involved in distant recurrence and indicates that R-Ras and Transgelin are potential post-surgical prognostic biomarkers for Stage III colorectal cancer
We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.